{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:47:52Z","timestamp":1788814072566,"version":"build-2803163510"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00277-025-06238-9","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T19:09:52Z","timestamp":1741374592000},"page":"2051-2054","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Twin pregnancy during treatment with asciminib for chronic myeloid leukemia \u2013 a case report"],"prefix":"10.1007","volume":"104","author":[{"given":"G\u00e9ssika B. G. M.","family":"Gutierrez de Moraes Pereira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor A.","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo Victor R.","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Cralcev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice V.","family":"de Jesus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana B.","family":"Spadoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa Vilela V.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Paulo C.","family":"Magalh\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gislaine O.","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme","family":"Duffles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe S.","family":"Maia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Surita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Paulo S.","family":"Guida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmino Antonio","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Laura","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7975-0805","authenticated-orcid":false,"given":"Katia B. B.","family":"Pagnano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,8]]},"reference":[{"issue":"10","key":"6238_CR1","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O\u2019Brien SG, Druker BJ (2017) IRIS Investigators. Long-term outcomes of Imatinib Treatment for chronic myeloid leukemia. N Engl J Med 376(10):917\u2013927. https:\/\/doi.org\/10.1056\/NEJMoa1609324. https:\/\/pubmed.ncbi.nlm.nih.gov\/28273028\/","journal-title":"N Engl J Med"},{"key":"6238_CR2","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1007\/s10815-021-02181-6","volume":"38","author":"A Rambhatla","year":"2021","unstructured":"Rambhatla A, Strug MR, De Paredes JG et al (2021) Fertility considerations in targeted biologic therapy with tyrosine kinase inhibitors: a review. J Assist Reprod Genet 38:1897\u20131908. https:\/\/doi.org\/10.1007\/s10815-021-02181-6","journal-title":"J Assist Reprod Genet"},{"key":"6238_CR3","doi-asserted-by":"publisher","first-page":"204062072096612","DOI":"10.1177\/2040620720966120","volume":"11","author":"E Abruzzese","year":"2020","unstructured":"Abruzzese E, Mauro M, Apperley J, Chelysheva E (2020) Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence, and recommendations. Ther Adv Hematol 11:2040620720966120. https:\/\/doi.org\/10.1177\/2040620720966120","journal-title":"Ther Adv Hematol"},{"key":"6238_CR4","unstructured":"Scemblix (2023) (asciminib) [package insert]. East Hanover NJ: Novartis Pharmaceuticals Corporation"},{"issue":"7647","key":"6238_CR5","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nature21702","volume":"543","author":"AA Wylie","year":"2017","unstructured":"Wylie AA, Schoepfer J, Jahnke W, Cowan-Jacob SW, Loo A, Furet P et al (2017) The allosteric inhibitor ABL001 enables dual targeting of BCR\u2013ABL1. Nature 543(7647):733\u2013737","journal-title":"Nature"},{"issue":"1","key":"6238_CR6","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13045-024-01642-6","volume":"17","author":"TP Hughes","year":"2024","unstructured":"Hughes TP, Saglio G, Geissler J, Kim DW, Lomaia E, Mayer J, Turkina A, Kapoor S, Cardoso AP, Nieman B, Quenet S, Cortes JE (2024) Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study. J Hematol Oncol 17(1):125. https:\/\/doi.org\/10.1186\/s13045-024-01642-6PMID: 39696526; PMCID: PMC11657281","journal-title":"J Hematol Oncol"},{"issue":"21","key":"6238_CR7","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1182\/blood.2020009984","volume":"138","author":"D R\u00e9a","year":"2021","unstructured":"R\u00e9a D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, Turkina A, Kim DW, Apperley JF, Abdo A, Fogliatto LM, Kim DDH, le Coutre P, Saussele S, Annunziata M, Hughes TP, Chaudhri N, Sasaki K, Chee L, Garc\u00eda-Guti\u00e9rrez V, Cortes JE, Aimone P, Allepuz A, Quenet S, B\u00e9doucha V, Hochhaus A (2021) A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood 138(21):2031\u20132041. https:\/\/doi.org\/10.1182\/blood.2020009984","journal-title":"Blood"},{"issue":"3","key":"6238_CR8","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41375-023-01829-9","volume":"37","author":"A Hochhaus","year":"2023","unstructured":"Hochhaus A, R\u00e9a D, Boquimpani C, Minami Y, Cortes JE, Hughes TP, Apperley JF, Lomaia E, Voloshin S, Turkina A, Kim DW, Abdo A, Fogliatto LM, le Coutre P, Sasaki K, Kim DDH, Saussele S, Annunziata M, Chaudhri N, Chee L, Garc\u00eda-Guti\u00e9rrez V, Kapoor S, Allepuz A, Quenet S, B\u00e9doucha V, Mauro MJ (2023) Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia 37(3):617\u2013626. https:\/\/doi.org\/10.1038\/s41375-023-01829-9Epub 2023 Jan 30","journal-title":"Leukemia"},{"key":"6238_CR9","unstructured":"Abruzzese E Chronic myeloid leukemia and pregnancy. Presented at: 11th Annual Meeting of the Society of Hematologic Oncology (SOHO 2023). September 8, 2023. Houston, TX"},{"key":"6238_CR10","doi-asserted-by":"crossref","unstructured":"Andrew J, Innes C, Hayden V, Orovboni D, Rees S, Claudiani F, Fernando A, Khan J, Byrne P, Gallipoli S, Francis M, Copland G, Horne M, Raghavan P, Garland G, Hannah (2022) Sandra Hassan, Brian James Patrick Huntly, Jissan Husain, Sudhakaran Makkuni, Kate Rothwell, Letizia Foroni, Jane F. Apperley, Dragana Milojkovic; Real-World Experience of Asciminib: Factors Associated with Response. Blood; 140 (Supplement 1): 6796\u20136797. doi","DOI":"10.1182\/blood-2022-165501"},{"issue":"Supplement 1","key":"6238_CR11","doi-asserted-by":"publisher","first-page":"6603","DOI":"10.1182\/blood-2024-208360","volume":"144","author":"B Katia","year":"2024","unstructured":"Katia B, Pagnano IA, de Siqueira Gde, Campos NCR, Guerrero, Johnny FC, Camargo GO, Duarte G, Duffles, Victor H, Guidini B, Sabioni FS, Seguro (2024) Nelson Hamerschlak, Morgani Rodrigues, Emanuella Graciott Souza, Patricia Santos Resende Cardoso, Gustavo HR Magalh\u00e3es, Acy Telles De Souza Quixada, Adriana Seber, Ires Hamyra Bezerra Massaut, Laura Maria Fogliatto, Natalia Nunes Gon\u00e7alves, Rafael De S\u00e1 Vasconcelos, Simone Vidor, Carmino De Souza, Vaneuza Funke; Asciminib in patients with chronic myeloid leukemia who failed two or more tyrosine kinase inhibitors - clinical outcomes from a Managed Access Program in Brazil. Blood 144(Supplement 1):6603. https:\/\/doi.org\/10.1182\/blood-2024-208360","journal-title":"Blood"},{"issue":"6","key":"6238_CR12","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/ejh.13167","volume":"101","author":"M Balsat","year":"2018","unstructured":"Balsat M, Etienne M, Elhamri M, Hayette S, Salles G, Thomas X (2018) Successful pregnancies in patients with BCR-ABL-positive leukemias treated with interferon-alpha therapy during the tyrosine kinase inhibitors era. Eur J Haematol 101(6):774\u2013780. https:\/\/doi.org\/10.1111\/ejh.13167Epub 2018 Oct 8","journal-title":"Eur J Haematol"},{"key":"6238_CR13","doi-asserted-by":"publisher","unstructured":"Moura AC, Delamain MT, Duarte GBO, Lorand-Metze I, Souza CA, Pagnano KBB (2019 Apr-Jun) Management of chronic myeloid leukemia during pregnancy: a retrospective analysis at a single center. Hematol Transfus Cell Ther 41(2):125\u2013128. https:\/\/doi.org\/10.1016\/j.htct.2018.10.001Epub 2019 Feb 18","DOI":"10.1016\/j.htct.2018.10.001"},{"issue":"4","key":"6238_CR14","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.clml.2023.11.011","volume":"24","author":"E Abruzzese","year":"2024","unstructured":"Abruzzese E, Trawinska MM, De Fabritiis P, Bernardi S (2024) SOHO State of the art updates and next questions: chronic myeloid leukemia and pregnancy: per Aspera Ad Astra. Clin Lymphoma Myeloma Leuk 24(4):214\u2013223 Epub 2023 Dec 12","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"6238_CR15","doi-asserted-by":"publisher","first-page":"5505","DOI":"10.1182\/blood-2007-10-114900","volume":"111","author":"M Seonaid","year":"2008","unstructured":"Seonaid M, Pye J, Cortes P, Ault A, Hatfield H, Kantarjian R, Pilot G, Rosti, Jane F, Apperley (2008) The effects of imatinib on pregnancy outcome. Blood 111(12):5505\u20135508. https:\/\/doi.org\/10.1182\/blood-2007-10-114900","journal-title":"Blood"},{"issue":"Suppl 2","key":"6238_CR16","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00277-015-2317-z","volume":"94","author":"R Palani","year":"2015","unstructured":"Palani R, Milojkovic D, Apperley JF (2015) Managing pregnancy in chronic myeloid leukaemia. Ann Hematol 94(Suppl 2):167\u2013176. https:\/\/doi.org\/10.1007\/s00277-015-2317-z","journal-title":"Ann Hematol"},{"key":"6238_CR17","doi-asserted-by":"publisher","first-page":"101127","DOI":"10.1016\/j.preghy.2024.101127","volume":"36","author":"AC Staff","year":"2024","unstructured":"Staff AC, Costa ML, Dechend R, Jacobsen DP, Sugulle M (2024) Hypertensive disorders of pregnancy and long-term maternal cardiovascular risk: bridging epidemiological knowledge into personalized postpartum care and follow-up. Pregnancy Hypertens 36:101127. https:\/\/doi.org\/10.1016\/j.preghy.2024.101127Epub 2024 Apr 21","journal-title":"Pregnancy Hypertens"},{"key":"6238_CR18","doi-asserted-by":"publisher","first-page":"g2301","DOI":"10.1136\/bmj.g2301","volume":"348","author":"K Bramham","year":"2014","unstructured":"Bramham K, Parnell B, Nelson-Piercy C, Seed PT, Poston L, Chappell LC (2014) Chronic hypertension and pregnancy outcomes: systematic review and meta-analysis. BMJ 348:g2301. https:\/\/doi.org\/10.1136\/bmj.g2301","journal-title":"BMJ"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06238-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06238-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06238-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T06:11:13Z","timestamp":1745561473000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06238-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["6238"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06238-9","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"3 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the patient for the publication of this case report. The study was approved by the ethics committee of University of Campinas.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Katia Pagnano has received research support from EMS, speaker honorarium from Novartis, Teva, Pintpharma, Pfizer and is consultant to Novartis and Pfizer. The other authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}